Edition:
United States

Kindred Biosciences Announces Positive Results From Pilot Effectiveness Study


Tuesday, 30 Oct 2018 04:01pm EDT 

Oct 30 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES POSITIVE RESULTS FROM PILOT EFFECTIVENESS STUDY OF ITS FULLY CANINIZED IL-31 ANTIBODY FOR THE TREATMENT OF ATOPIC DERMATITIS IN DOGS AND ISSUANCE OF U.S. PATENT.KINDRED BIOSCIENCES INC - STATISTICALLY SIGNIFICANT REDUCTION IN PRURITUS VERSUS PLACEBO WAS ACHIEVED ACROSS ALL DOSE GROUPS.KINDRED BIOSCIENCES INC - U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED A PATENT (PATENT NO. 10,093,731) FOR KINDREDBIO'S ANTI-IL31 ANTIBODY.KINDRED BIOSCIENCES INC - BASED ON A PRELIMINARY REVIEW OF SAFETY DATA, IL-31 DRUG APPEARS TO BE WELL TOLERATED. 

Company Quote

11.89
-0.37 -3.02%
14 Dec 2018